Education
About Us
Working with TipRanks
Follow Us
Lineage Cell Therapeutics, Inc. (LCTX)
:LCTX
LCTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.37 - $1.21
Previous CloseN/A
Volume522.43K
Average Volume (3M)1.44M
Market Cap
$230.64M
Enterprise Value$165.80M
Total Cash (Recent Filing)$42.29M
Total Debt (Recent Filing)$2.15M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Nov 05, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding228,356,300
10 Day Avg. Volume1,106,652
30 Day Avg. Volume1,436,160
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue15.19
Enterprise Value/Gross Profit15.57
Enterprise Value/Ebitda-8.32
Forecast
1Y Price Target
$4.00Price Target Upside292.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsThe first chronic spinal cord injury (SCI) patient has been treated in the study using a new delivery system, marking a significant advancement in the treatment approach.
Financial StabilityThe company ended the period with $42.3M in cash, which is expected to provide runway into 1Q27 and may be extended by additional collaboration agreements or milestones from Roche.
Partnership And InvestmentPartner Roche/Genentech is enrolling in the P2a GAlette study to optimize OpRegen delivery for geographic atrophy, showing investment and appreciation of its potential.
Bears Say
CompetitionUnprecedented data continue to excite in a big way vs. approved GA products.
Market ConditionsLineage has also taken steps to shore up its balance sheet with runway into 2027, and combined with more favorable market conditions in Biotech (for cell therapy in particular), the discount rate is lowered to 30%, from 35%.
Lineage Therap News
LCTX FAQ
What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest stock price was $0.36 and its highest was $1.21 in the past 12 months.
What is Lineage Cell Therapeutics, Inc.’s market cap?
Lineage Cell Therapeutics, Inc.’s market cap is $230.64M.
When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 82 days.
How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
Lineage Cell Therapeutics, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.027 by -$0.103.
Is Lineage Cell Therapeutics, Inc. overvalued?
According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. does not currently pay dividends.
What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
Lineage Cell Therapeutics, Inc.’s EPS estimate is -0.03.
How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
Lineage Cell Therapeutics, Inc. has 228,356,300 shares outstanding.
What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
Lineage Cell Therapeutics, Inc. reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.027. Following the earnings report the stock price went up 1.98%.
Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LCTX
Lineage Therap Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (292.16% Upside)
$4.00 (292.16% Upside)
Hedge Fund Trend
Decreased
By 6.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.24%
12-Months-Change
Fundamentals
Return on Equity
-70.12%
Trailing 12-Months
Asset Growth
-11.68%
Trailing 12-Months
Company Description
Lineage Cell Therapeutics, Inc.
Lineage Therap (LCTX) is a biotechnology company focused on developing innovative cell therapies for the treatment of degenerative diseases and conditions, particularly those affecting the retina. The company specializes in the advancement of pluripotent stem cell technology, which allows for the generation of specialized cells that can potentially restore vision in patients suffering from retinal disorders. Lineage's core products include its lead therapeutic candidates, which are designed to address unmet medical needs in ocular health, as well as other applications in regenerative medicine.
LCTX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights significant progress in OpRegen and OPC1 programs, coupled with a major manufacturing milestone that positions Lineage for further growth and partnerships. However, uncertainties around Genentech's decision-making timeline and data access, alongside potential enrollment challenges for OPC1, present notable concerns.View all LCTX earnings summariesLCTX Stock 12 Month Forecast
Average Price Target
$4.00
▲(292.16% Upside)
Technical Analysis
Cellectis SA
―
Editas Medicine
―
Nkarta
―
Neumora Therapeutics, Inc.
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
58.68% Insiders
6.19% Mutual Funds
0.03% Other Institutional Investors
30.82% Public Companies and
Individual Investors